Matching articles for "Vituz"
Issue 1562 · December 17, 2018 Free
Drugs for Cough

Acute cough (<3 weeks in duration) generally does not require pharmacologic treatment, especially in children. Suppression of productive cough may be harmful. Management of patients with cough should include…

Med Lett Drugs Ther. 2018 Dec 17; 60(1562):206-8
Acute cough (<3 weeks in duration) generally does not require pharmacologic treatment, especially in children. Suppression of productive cough may be harmful. Management of patients with cough should include elimination of any precipitating factor (e.g., cigarette smoking) and treatment of any underlying cause such as upper airway cough syndrome, gastroesophageal reflux disease, asthma, or other pulmonary disease.
Issue 1453 · October 13, 2014
Rescheduling of Hydrocodone Combination Products

The Drug Enforcement Administration (DEA) has reclassified all hydrocodone combination products as schedule II controlled substances; they were previously classified as schedule III. Hydrocodone alone (Zohydro…

Med Lett Drugs Ther. 2014 Oct 13; 56(1453):101-2
The Drug Enforcement Administration (DEA) has reclassified all hydrocodone combination products as schedule II controlled substances; they were previously classified as schedule III. Hydrocodone alone (Zohydro ER) is already a schedule II controlled substance.
Issue 1430 · November 25, 2013
Hydrocodone/Chlorpheniramine (Vituz)

An oral solution ( Vituz – Hawthorne) containing two old drugs, the centrally-acting opioid hydrocodone bitartrate and the first-generation H 1 -antihistamine chlorpheniramine maleate, has been approved by…

Med Lett Drugs Ther. 2013 Nov 25; 55(1430):95-6
An oral solution ( Vituz – Hawthorne) containing two old drugs, the centrally-acting opioid hydrocodone bitartrate and the first-generation H 1 -antihistamine chlorpheniramine maleate, has been approved by the FDA for relief of cough and [other] symptoms associated with upper respiratory allergies or a common cold in adults. Several extended-release products containing hydrocodone and chlorpheniramine are available as capsules and suspensions and have been used for years for similar indications. Vituz is classified as a schedule III controlled substance, but the FDA has asked the DEA to reclassify hydrocodone products as schedule II.